Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a ...

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...

MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...

Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...

14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- ...

The Company's stock option plan is a 10% rolling plan. As of the date hereof, a total of 6,556,610 common shares of the Company are reserved for issuance under the Company's stock option plan, with ...

Proprietary Magnetic Patch System Delivers Regenerative Peptides to Targeted Tissue Without Injection, with Built-In Confirmation of Successful Delivery MEQUON, Wis., June 30, 2026 /PRNewswire/ -- ...

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.